Inside the BEGONIA Methodology: What Most Summaries Skip

At a glance

| Parameter | Detail | |---|---| | N | 949 (randomized) | | Intervention | Flibanserin 100 mg once daily at bedtime | | Comparator | Matching placebo | | Duration | 24 weeks (with 4-week screening, 4-week single-blind placebo run-in) | | Primary endpoint | Change from baseline in number of satisfying sexual events (SSEs) over 28 days | | Key co-primary | Change from baseline in desire score (eDiary) | | Key result | Statistically significant improvement vs. placebo on SSEs and desire; effect sizes were modest |

Why the methodology matters more than the p-value

Most summaries of the BEGONIA trial report the headline: flibanserin improved satisfying sexual events and desire in premenopausal women with HSDD. That is accurate but incomplete. The clinical meaning of those improvements depends entirely on how the trial was structured, who was enrolled, what "satisfying" meant, and how the statistical plan handled multiplicity. This page breaks each of those decisions open.

Trial architecture: screening, run-in, and randomization

BEGONIA used a four-phase structure. A 4-week screening period confirmed the HSDD diagnosis (per DSM-IV-TR criteria). That was followed by a 4-week, single-blind placebo run-in period before randomization.

The run-in served two purposes. First, it established a stable baseline for SSE and desire diary scores. Second, it screened out placebo responders, women whose symptoms improved substantially on placebo alone. Removing early placebo responders is a common strategy in psychiatric and sexual-medicine trials. It inflates the apparent drug-placebo difference by excluding participants most likely to improve regardless of treatment. The FDA's own guidance on enrichment designs acknowledges that this approach can increase assay sensitivity but may limit generalizability.

After the run-in, 949 women were randomized 1:1 to flibanserin 100 mg or placebo. Randomization was stratified by site. The allocation sequence was computer-generated, and both participants and investigators were blinded.

Who got in (and who didn't)

Inclusion criteria required premenopausal women aged 18 and older with generalized, acquired HSDD per DSM-IV-TR. They needed to be in a stable, monogamous sexual relationship for at least one year and report distress about their low desire, measured by the Female Sexual Distress Scale-Revised (FSDS-R).

Key exclusion criteria removed women with:

• Any other sexual dysfunction as the primary complaint (e.g., dyspareunia, anorgasmia)
• Major depressive disorder or current use of antidepressants
• Substance-use disorders
• Hormonal causes of low desire (e.g., uncontrolled thyroid disease)
• Use of hormonal contraceptives containing anti-androgens

These criteria created a "clean" HSDD population. That is useful for isolating a drug signal but does not reflect the typical clinical patient, who often has overlapping sexual complaints, comorbid mood disorders, or concurrent SSRI use. The exclusion of antidepressant users is especially relevant. SSRIs are a leading cause of acquired low desire, and many women presenting to their prescriber with HSDD are already on one.

The endpoint question: what counts as "satisfying"?

The co-primary endpoints were (1) change from baseline in the number of SSEs over 28 days and (2) change from baseline in desire score, captured via a daily electronic diary (eDiary).

SSE counting relied on participant self-report through the eDiary system. After each sexual event, women recorded whether it was "satisfying." There was no external validation, no partner corroboration, and no standardized definition of satisfaction provided beyond the participant's own judgment. This is standard for the field, but it introduces subjectivity. A woman's threshold for labeling an event "satisfying" can shift over 24 weeks simply from being enrolled in a trial and attending study visits.

The desire score came from a single daily eDiary question asking women to rate their level of sexual desire. This was averaged over 28-day windows. The BEGONIA publication reports the desire endpoint as a change in a 0-to-4 scale score. At that resolution, statistically significant differences can be fractions of a point.

The BEGONIA Endpoint Interpretation Framework

To translate trial numbers into clinical meaning, consider three questions for any HSDD trial endpoint:

1. Absolute magnitude: How many additional SSEs per month? A gain of 0.5 to 1.0 SSE/month is statistically detectable in a large trial. Whether a patient considers one extra satisfying event every four to eight weeks meaningful is a separate question.
2. Responder analysis: What fraction of treated women crossed a clinically relevant threshold? The BEGONIA publication reports mean changes. A responder analysis (e.g., proportion achieving ≥2 additional SSEs) would reveal whether benefits were concentrated in a subgroup or spread thinly.
3. Distress reduction: HSDD is defined by distress, not just low desire. The FSDS-R "desire" item and total score were secondary endpoints. Reductions in distress were statistically significant, and arguably more clinically relevant than SSE counts.

Statistical design and multiplicity

The trial used a mixed-model repeated-measures (MMRM) analysis with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline value as a covariate. MMRM is appropriate for longitudinal data with potential dropout because it uses all available observations without requiring imputation.

For the co-primary endpoints, BEGONIA applied a fixed-sequence (gatekeeping) procedure. SSE change was tested first at alpha = 0.05. Only if it reached significance was desire change tested. This protects the family-wise error rate, but it also means that if the SSE endpoint had narrowly missed significance, desire data would have been left formally untested regardless of its p-value.

The sample size was powered to detect a treatment difference of approximately 1.0 SSE per 28-day cycle with 90% power. That target reflects a relatively small effect size, which is consistent with what the trial ultimately observed.

What the numbers actually showed

The primary results at 24 weeks:

| Endpoint | Flibanserin (LS mean change) | Placebo (LS mean change) | Difference | p-value | |---|---|---|---|---| | SSEs per 28 days | +1.6 | +0.8 | +0.8 | p = 0.006 | | Desire score (eDiary) | +0.3 | +0.1 | +0.2 | p < 0.001 | | FSDS-R desire item | -0.7 | -0.4 | -0.3 | p < 0.001 | | FSDS-R total score | -4.6 | -2.7 | -1.9 | p < 0.001 |

The placebo group gained nearly one additional SSE per month. The drug group gained about 1.6. The drug-attributable difference: 0.8 SSEs per 28-day cycle. That is less than one additional satisfying sexual event per month above what placebo provided.

For the desire score, the absolute difference was 0.2 points on a 0-to-4 scale. On any individual day, this difference would be undetectable. Across a population of nearly 950 women measured repeatedly over 24 weeks, it reached high statistical significance.

The placebo response problem

A placebo response of +0.8 SSEs (roughly equal to the drug-specific gain) is not unusual in HSDD trials. The act of enrolling, tracking sexual activity daily, and attending clinic visits may itself alter sexual behavior and perception. The Jaspers et al. 2016 meta-analysis of flibanserin trials across the development program confirmed consistently large placebo responses, typically accounting for 40-60% of the total improvement seen in the drug arm.

This does not mean flibanserin is ineffective. It means that the absolute benefit attributable to the drug is small, and a meaningful portion of what patients experience in practice may come from non-pharmacological factors like increased attention to sexuality, partner communication prompted by study participation, and expectation effects.

Safety signals that shaped the FDA narrative

BEGONIA's safety data showed the expected side effects: dizziness (11.4% vs. 2.1%), somnolence (11.2% vs. 1.5%), nausea (10.4% vs. 3.6%), and fatigue (6.5% vs. 1.9%). These are central-nervous-system effects consistent with flibanserin's serotonergic and dopaminergic activity.

The more consequential safety issue, alcohol interaction causing severe hypotension and syncope, was not fully characterized in BEGONIA. It emerged more clearly in dedicated interaction studies and became central to the FDA's Risk Evaluation and Mitigation Strategy (REMS) requirement when Addyi was approved in August 2015. The REMS mandated that prescribers complete training and that patients avoid alcohol entirely while taking flibanserin.

Limitations the authors acknowledged

The BEGONIA investigators noted several limitations:

• The study population was predominantly White (86%), limiting generalizability across racial and ethnic groups.
• The requirement for a stable monogamous relationship excluded single women and those in newer or non-monogamous partnerships.
• The 24-week duration, while longer than many psychiatric trials, may not capture how desire and satisfaction evolve over years of treatment.
• The placebo run-in may have excluded women who would have responded to either treatment or placebo, narrowing the apparent treatment population.

One limitation not discussed in the publication: the DSM-IV-TR diagnosis of HSDD was replaced by the DSM-5 category of Female Sexual Interest/Arousal Disorder (FSIAD) in 2013, one year before BEGONIA's publication. FSIAD merges low desire and low arousal into a single diagnosis. A trial enrolling under FSIAD criteria might capture a different patient mix than one using the older HSDD definition.

How BEGONIA fits the broader flibanserin program

BEGONIA was one of several Phase III trials (alongside DAISY, VIOLET, and SNOWDROP for postmenopausal women) in flibanserin's development. The FDA's 2015 approval considered data across the program. Flibanserin had been rejected twice before approval (in 2010 and 2013), with the FDA citing insufficient efficacy relative to side effects. The third review, supported by an advisory committee vote of 18-6 in favor, reflected both additional data and advocacy pressure from the "Even the Score" campaign arguing for gender equity in sexual-dysfunction treatments.

The ISSWSH process-of-care guidelines for HSDD position flibanserin as a treatment option for premenopausal women alongside counseling and other pharmacologic options, recommending shared decision-making that includes realistic expectations about the magnitude of benefit.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the BEGONIA trial. J Sex Med. 2012;9(2):560-577. PubMed
2. FDA. Addyi (flibanserin) prescribing information. Revised 2019. FDA Label
3. Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453-462. PubMed
4. Derogatis LR, Clayton AH, Lewis-D'Agostino D, et al. Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008;5(2):357-364. PubMed
5. Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions: Part II. J Sex Med. 2016;13(12):1888-1906. PubMed
6. FDA. Enrichment strategies for clinical trials to support approval of human drugs and biological products: guidance for industry. 2019. FDA Guidance